Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients
•Largest study of rituximab in MOG-IgG-associated disorder, includes both adults and children.•Rituximab reduced relapse rates in MOG-IgG-associated disorder by 37%.•Compared to similar studies in AQP4-IgG-associated NMOSD, the efficacy seems lower.•Some patients relapsed despite apparent circulatin...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis and related disorders Jg. 44; S. 102251 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Netherlands
Elsevier B.V
01.09.2020
Elsevier |
| Schlagworte: | |
| ISSN: | 2211-0348, 2211-0356, 2211-0356, 2211-0348 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | •Largest study of rituximab in MOG-IgG-associated disorder, includes both adults and children.•Rituximab reduced relapse rates in MOG-IgG-associated disorder by 37%.•Compared to similar studies in AQP4-IgG-associated NMOSD, the efficacy seems lower.•Some patients relapsed despite apparent circulating B-cell depletion.
To assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD).
Retrospective review of RTX-treated MOGAD patients from 29 centres in 13 countries. The primary outcome measure was change in relapse rate after starting rituximab (Poisson regression model).
Data on 121 patients were analysed, including 30 (24.8%) children. Twenty/121 (16.5%) were treated after one attack, of whom 14/20 (70.0%) remained relapse-free after median (IQR) 11.2 (6.3–14.1) months. The remainder (101/121, 83.5%) were treated after two or more attacks, of whom 53/101 (52.5%) remained relapse-free after median 12.1 (6.3–24.9) months. In this ‘relapsing group’, relapse rate declined by 37% (95%CI=19–52%, p<0.001) overall, 63% (95%CI=35–79%, p = 0.001) when RTX was used first line (n = 47), and 26% (95%CI=2–44%, p = 0.038) when used after other steroid-sparing immunotherapies (n = 54). Predicted 1-year and 2-year relapse-free survival was 79% and 55% for first-line RTX therapy, and 38% and 18% for second-/third-line therapy. Circulating CD19+B-cells were suppressed to <1% of total circulating lymphocyte population at the time of 45/57 (78.9%) relapses.
RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion. Prospective controlled studies are needed to validate these results. |
|---|---|
| AbstractList | •Largest study of rituximab in MOG-IgG-associated disorder, includes both adults and children.•Rituximab reduced relapse rates in MOG-IgG-associated disorder by 37%.•Compared to similar studies in AQP4-IgG-associated NMOSD, the efficacy seems lower.•Some patients relapsed despite apparent circulating B-cell depletion.
To assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD).
Retrospective review of RTX-treated MOGAD patients from 29 centres in 13 countries. The primary outcome measure was change in relapse rate after starting rituximab (Poisson regression model).
Data on 121 patients were analysed, including 30 (24.8%) children. Twenty/121 (16.5%) were treated after one attack, of whom 14/20 (70.0%) remained relapse-free after median (IQR) 11.2 (6.3–14.1) months. The remainder (101/121, 83.5%) were treated after two or more attacks, of whom 53/101 (52.5%) remained relapse-free after median 12.1 (6.3–24.9) months. In this ‘relapsing group’, relapse rate declined by 37% (95%CI=19–52%, p<0.001) overall, 63% (95%CI=35–79%, p = 0.001) when RTX was used first line (n = 47), and 26% (95%CI=2–44%, p = 0.038) when used after other steroid-sparing immunotherapies (n = 54). Predicted 1-year and 2-year relapse-free survival was 79% and 55% for first-line RTX therapy, and 38% and 18% for second-/third-line therapy. Circulating CD19+B-cells were suppressed to <1% of total circulating lymphocyte population at the time of 45/57 (78.9%) relapses.
RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion. Prospective controlled studies are needed to validate these results. To assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD).OBJECTIVETo assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD).Retrospective review of RTX-treated MOGAD patients from 29 centres in 13 countries. The primary outcome measure was change in relapse rate after starting rituximab (Poisson regression model).METHODSRetrospective review of RTX-treated MOGAD patients from 29 centres in 13 countries. The primary outcome measure was change in relapse rate after starting rituximab (Poisson regression model).Data on 121 patients were analysed, including 30 (24.8%) children. Twenty/121 (16.5%) were treated after one attack, of whom 14/20 (70.0%) remained relapse-free after median (IQR) 11.2 (6.3-14.1) months. The remainder (101/121, 83.5%) were treated after two or more attacks, of whom 53/101 (52.5%) remained relapse-free after median 12.1 (6.3-24.9) months. In this 'relapsing group', relapse rate declined by 37% (95%CI=19-52%, p<0.001) overall, 63% (95%CI=35-79%, p = 0.001) when RTX was used first line (n = 47), and 26% (95%CI=2-44%, p = 0.038) when used after other steroid-sparing immunotherapies (n = 54). Predicted 1-year and 2-year relapse-free survival was 79% and 55% for first-line RTX therapy, and 38% and 18% for second-/third-line therapy. Circulating CD19+B-cells were suppressed to <1% of total circulating lymphocyte population at the time of 45/57 (78.9%) relapses.RESULTSData on 121 patients were analysed, including 30 (24.8%) children. Twenty/121 (16.5%) were treated after one attack, of whom 14/20 (70.0%) remained relapse-free after median (IQR) 11.2 (6.3-14.1) months. The remainder (101/121, 83.5%) were treated after two or more attacks, of whom 53/101 (52.5%) remained relapse-free after median 12.1 (6.3-24.9) months. In this 'relapsing group', relapse rate declined by 37% (95%CI=19-52%, p<0.001) overall, 63% (95%CI=35-79%, p = 0.001) when RTX was used first line (n = 47), and 26% (95%CI=2-44%, p = 0.038) when used after other steroid-sparing immunotherapies (n = 54). Predicted 1-year and 2-year relapse-free survival was 79% and 55% for first-line RTX therapy, and 38% and 18% for second-/third-line therapy. Circulating CD19+B-cells were suppressed to <1% of total circulating lymphocyte population at the time of 45/57 (78.9%) relapses.RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion. Prospective controlled studies are needed to validate these results.CONCLUSIONRTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion. Prospective controlled studies are needed to validate these results. Objective: to assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD).Methods: Retrospective review of RTX-treated MOGAD patients from 29 centres in 13 countries. The primary outcome measure was change in relapse rate after starting rituximab (Poisson regression model).Results: Data on 121 patients were analysed, including 30 (24.8%) children. Twenty/121 (16.5%) were treated after one attack, of whom 14/20 (70.0%) remained relapse-free after median (IQR) 11.2 (6.3-14.1) months. The remainder (101/121, 83.5%) were treated after two or more attacks, of whom 53/101 (52.5%) remained relapse-free after median 12.1 (6.3-24.9) months. In this 'relapsing group', relapse rate declined by 37% (95%CI=19-52%, p<0.001) overall, 63% (95%CI=35-79%, p = 0.001) when RTX was used first line (n = 47), and 26% (95%CI=2-44%, p = 0.038) when used after other steroid-sparing immunotherapies (n = 54). Predicted 1-year and 2-year relapse-free survival was 79% and 55% for first-line RTX therapy, and 38% and 18% for second-/third-line therapy. Circulating CD19+B-cells were suppressed to <1% of total circulating lymphocyte population at the time of 45/57 (78.9%) relapses.Conclusion: RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion. Prospective controlled studies are needed to validate these results. To assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD). Retrospective review of RTX-treated MOGAD patients from 29 centres in 13 countries. The primary outcome measure was change in relapse rate after starting rituximab (Poisson regression model). Data on 121 patients were analysed, including 30 (24.8%) children. Twenty/121 (16.5%) were treated after one attack, of whom 14/20 (70.0%) remained relapse-free after median (IQR) 11.2 (6.3-14.1) months. The remainder (101/121, 83.5%) were treated after two or more attacks, of whom 53/101 (52.5%) remained relapse-free after median 12.1 (6.3-24.9) months. In this 'relapsing group', relapse rate declined by 37% (95%CI=19-52%, p<0.001) overall, 63% (95%CI=35-79%, p = 0.001) when RTX was used first line (n = 47), and 26% (95%CI=2-44%, p = 0.038) when used after other steroid-sparing immunotherapies (n = 54). Predicted 1-year and 2-year relapse-free survival was 79% and 55% for first-line RTX therapy, and 38% and 18% for second-/third-line therapy. Circulating CD19 B-cells were suppressed to <1% of total circulating lymphocyte population at the time of 45/57 (78.9%) relapses. RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion. Prospective controlled studies are needed to validate these results. Highlights•Largest study of rituximab in MOG-IgG-associated disorder, includes both adults and children. •Rituximab reduced relapse rates in MOG-IgG-associated disorder by 37%. •Compared to similar studies in AQP4-IgG-associated NMOSD, the efficacy seems lower. •Some patients relapsed despite apparent circulating B-cell depletion. |
| ArticleNumber | 102251 |
| Author | Pittock, Sean Marignier, Romain Jelcic, Ilijas Gornall, Matthew Hemingway, Cheryl Lutterotti, Andreas Maillart, Elisabeth Lopez-Chiriboga, A Sebastian Mathey, Guillaume Bennett, Jeffrey L Deschamps, Romain Kaneko, Kimihiko Paul, Friedemann Cohen, Mikaël Palace, Jacqueline Pandit, Lekha Brandt, Alexander Laplaud, David Sato, Douglas Kazutoshi Oliveira, Luana Micheli Webb, Stewart Hunt, David Karthikeayan, Venkatraman Chitnis, Tanuja Reindl, Markus Matiello, Marcelo Gibbons, Emily Fujihara, Kazuo Cobo-Calvo, Alvaro Biotti, Damien Berger, Thomas Whittam, Daniel H Jacob, Anu Brochet, Bruno Tourbah, Ayman Pardo, Santiago Rostasy, Kevin Leite, M Isabel Wildemann, Brigitte Callegaro, Dagoberto Jarius, Sven Nakashima, Ichiro Audoin, Bertrand Tenembaum, Silvia Ciron, Jonathan Kim, Su-Hyun Kim, Ho Jin Weinshenker, Brian G Levy, Michael Capobianco, Marco Hacohen, Yael Lim, Ming Berek, Klaus Forsyth, Rob Gombolay, Grace Murray, Katy Misu, Tatsuro Neuteboom, Rinze Cicconi, Silvia Thouvenot, Eric Huda, Saif Solomon, Tom |
| AuthorAffiliation | m Tohoku University Graduate School of Medicine, Sendai, Japan v Pitié-Salpêtrière Hospital, APHP, Paris, France gg Department of Neuroinflammation, Queen Square MS Centre, UCL Institute of Neurology, London, United Kingdom s Hôpital Carémeau, Nimes University Hospital, Nimes, France a Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom cc Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, United Kingdom p Aix Marseille University, APHM, Hôpital de La Timone, Marseille, France y University Hospital of Purpan, Toulouse, France l Hospital das Clinicas Faculty of Medicine, University of São Paulo, São Paulo, Brazil aa Department of Paediatric Neurology, Erasmus MC-Sophia, Rotterdam, the Netherlands pp Research Institute and Hospital of National Cancer Center, Goyang, South Korea r Nantes University Hospital, Nantes, France o CHU de Bordeaux & INSERM U 1215, University of Bordeaux, Bordeaux, France q Nancy University Hospital an |
| AuthorAffiliation_xml | – name: m Tohoku University Graduate School of Medicine, Sendai, Japan – name: p Aix Marseille University, APHM, Hôpital de La Timone, Marseille, France – name: q Nancy University Hospital and Inserm CIC 1433, Nancy, France – name: l Hospital das Clinicas Faculty of Medicine, University of São Paulo, São Paulo, Brazil – name: dd Institute of Neuroscience, Newcastle University, Newcastle, United Kingdom – name: z Department of Pediatric Neurology, Children’s Hospital Datteln, University Witten/Herdecke, Witten, Germany – name: mm Nitte University, Mangaluru, Karnataka, India – name: bb Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, the Netherlands – name: h Medical University of Innsbruck, Innsbruck, Austria – name: x Fondation A. De Rothschild, Paris, France – name: kk Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan – name: s Hôpital Carémeau, Nimes University Hospital, Nimes, France – name: oo Pontificia Universidade Catolica Rio Grande Do Sul, Porto Alegre RS, Brazil – name: hh Children’s Neuroscience, Evelina London Children’s Hospital @ Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom – name: qq National Pediatric Hospital Dr. Juan P. Garrahan, Ciudad de Buenos Aires, Argentina – name: y University Hospital of Purpan, Toulouse, France – name: e Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States – name: ee Department of Neurology, Queen Elizabeth University Hospital, Glasgow, United Kingdom – name: aa Department of Paediatric Neurology, Erasmus MC-Sophia, Rotterdam, the Netherlands – name: f Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, United Kingdom – name: gg Department of Neuroinflammation, Queen Square MS Centre, UCL Institute of Neurology, London, United Kingdom – name: rr Department of Neurology, The Cleveland Clinic Abu Dhabi, United Arab Emirates – name: d Department of Neurology, Mayo Clinic, Rochester, Minnesota, United States – name: n Neurology Dept. - Regional MS Centre, S. Luigi University Hospital, Orbassano, Italy – name: j UniversitätsSpital Zürich, Zürich, Switzerland – name: k Emory & Children’s Pediatric Institute, Atlanta, Georgia, United States – name: w Poitiers University Hospital, Poitiers, France – name: g Experimental and Clinical Research Center Max Delbrueck Center for Molecular Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany – name: v Pitié-Salpêtrière Hospital, APHP, Paris, France – name: jj Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom – name: pp Research Institute and Hospital of National Cancer Center, Goyang, South Korea – name: a Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom – name: t Université Côte d’Azur, Centre Hospitalier Universitaire de Nice, Nice, France – name: u Reims University Hospital, University of Reims Champagne-Ardenne, Reims, LPN EA 2027, University of Paris VIII, Saint-Denis, France – name: r Nantes University Hospital, Nantes, France – name: ff Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, United Kingdom – name: ii Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom – name: b Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom – name: nn Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany – name: cc Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, United Kingdom – name: o CHU de Bordeaux & INSERM U 1215, University of Bordeaux, Bordeaux, France – name: c Pathologies de la Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, INSERM U1028, CNRS UMR 5292, Lyon 1 University, Center for Research in Neuroscience of Lyon, Lyon, France – name: i Department of Neurology, Medical University of Vienna, Vienna, Austria – name: ll Departments of Neurology and Ophthalmology, Program in Neuroscience, University of Colorado School of Medicine, Aurora, Colorado, United States |
| Author_xml | – sequence: 1 givenname: Daniel H orcidid: 0000-0002-9430-8190 surname: Whittam fullname: Whittam, Daniel H email: daniel.whittam@nhs.net organization: Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom – sequence: 2 givenname: Alvaro surname: Cobo-Calvo fullname: Cobo-Calvo, Alvaro organization: Pathologies de la Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, INSERM U1028, CNRS UMR 5292, Lyon 1 University, Center for Research in Neuroscience of Lyon, Lyon, France – sequence: 3 givenname: A Sebastian surname: Lopez-Chiriboga fullname: Lopez-Chiriboga, A Sebastian organization: Department of Neurology, Mayo Clinic, Rochester, Minnesota, United States – sequence: 4 givenname: Santiago surname: Pardo fullname: Pardo, Santiago organization: Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States – sequence: 5 givenname: Matthew surname: Gornall fullname: Gornall, Matthew organization: Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, United Kingdom – sequence: 6 givenname: Silvia surname: Cicconi fullname: Cicconi, Silvia organization: Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, United Kingdom – sequence: 7 givenname: Alexander surname: Brandt fullname: Brandt, Alexander organization: Experimental and Clinical Research Center Max Delbrueck Center for Molecular Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany – sequence: 8 givenname: Klaus orcidid: 0000-0003-2755-2043 surname: Berek fullname: Berek, Klaus organization: Medical University of Innsbruck, Innsbruck, Austria – sequence: 9 givenname: Thomas surname: Berger fullname: Berger, Thomas organization: Department of Neurology, Medical University of Vienna, Vienna, Austria – sequence: 10 givenname: Ilijas surname: Jelcic fullname: Jelcic, Ilijas organization: UniversitätsSpital Zürich, Zürich, Switzerland – sequence: 11 givenname: Grace surname: Gombolay fullname: Gombolay, Grace organization: Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States – sequence: 12 givenname: Luana Micheli surname: Oliveira fullname: Oliveira, Luana Micheli organization: Hospital das Clinicas Faculty of Medicine, University of São Paulo, São Paulo, Brazil – sequence: 13 givenname: Dagoberto surname: Callegaro fullname: Callegaro, Dagoberto organization: Hospital das Clinicas Faculty of Medicine, University of São Paulo, São Paulo, Brazil – sequence: 14 givenname: Kimihiko surname: Kaneko fullname: Kaneko, Kimihiko organization: Tohoku University Graduate School of Medicine, Sendai, Japan – sequence: 15 givenname: Tatsuro orcidid: 0000-0002-7311-2578 surname: Misu fullname: Misu, Tatsuro organization: Tohoku University Graduate School of Medicine, Sendai, Japan – sequence: 16 givenname: Marco surname: Capobianco fullname: Capobianco, Marco organization: Neurology Dept. - Regional MS Centre, S. Luigi University Hospital, Orbassano, Italy – sequence: 17 givenname: Emily surname: Gibbons fullname: Gibbons, Emily organization: Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom – sequence: 18 givenname: Venkatraman surname: Karthikeayan fullname: Karthikeayan, Venkatraman organization: Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom – sequence: 19 givenname: Bruno orcidid: 0000-0003-3824-2796 surname: Brochet fullname: Brochet, Bruno organization: CHU de Bordeaux & INSERM U 1215, University of Bordeaux, Bordeaux, France – sequence: 20 givenname: Bertrand surname: Audoin fullname: Audoin, Bertrand organization: Aix Marseille University, APHM, Hôpital de La Timone, Marseille, France – sequence: 21 givenname: Guillaume surname: Mathey fullname: Mathey, Guillaume organization: Nancy University Hospital and Inserm CIC 1433, Nancy, France – sequence: 22 givenname: David surname: Laplaud fullname: Laplaud, David organization: Nantes University Hospital, Nantes, France – sequence: 23 givenname: Eric surname: Thouvenot fullname: Thouvenot, Eric organization: Hôpital Carémeau, Nimes University Hospital, Nimes, France – sequence: 24 givenname: Mikaël orcidid: 0000-0002-3985-1297 surname: Cohen fullname: Cohen, Mikaël organization: Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France – sequence: 25 givenname: Ayman surname: Tourbah fullname: Tourbah, Ayman organization: Reims University Hospital, University of Reims Champagne-Ardenne, Reims, LPN EA 2027, University of Paris VIII, Saint-Denis, France – sequence: 26 givenname: Elisabeth surname: Maillart fullname: Maillart, Elisabeth organization: Pitié-Salpêtrière Hospital, APHP, Paris, France – sequence: 27 givenname: Jonathan orcidid: 0000-0002-3386-6308 surname: Ciron fullname: Ciron, Jonathan organization: Poitiers University Hospital, Poitiers, France – sequence: 28 givenname: Romain surname: Deschamps fullname: Deschamps, Romain organization: Fondation A. De Rothschild, Paris, France – sequence: 29 givenname: Damien orcidid: 0000-0003-0569-629X surname: Biotti fullname: Biotti, Damien organization: University Hospital of Purpan, Toulouse, France – sequence: 30 givenname: Kevin surname: Rostasy fullname: Rostasy, Kevin organization: Department of Pediatric Neurology, Children's Hospital Datteln, University Witten/Herdecke, Witten, Germany – sequence: 31 givenname: Rinze surname: Neuteboom fullname: Neuteboom, Rinze organization: Department of Paediatric Neurology, Erasmus MC-Sophia, Rotterdam, the Netherlands – sequence: 32 givenname: Cheryl surname: Hemingway fullname: Hemingway, Cheryl organization: Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, United Kingdom – sequence: 33 givenname: Rob surname: Forsyth fullname: Forsyth, Rob organization: Institute of Neuroscience, Newcastle University, Newcastle, United Kingdom – sequence: 34 givenname: Marcelo surname: Matiello fullname: Matiello, Marcelo organization: Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States – sequence: 35 givenname: Stewart surname: Webb fullname: Webb, Stewart organization: Department of Neurology, Queen Elizabeth University Hospital, Glasgow, United Kingdom – sequence: 36 givenname: David surname: Hunt fullname: Hunt, David organization: Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, United Kingdom – sequence: 37 givenname: Katy surname: Murray fullname: Murray, Katy organization: Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, United Kingdom – sequence: 38 givenname: Yael surname: Hacohen fullname: Hacohen, Yael organization: Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, United Kingdom – sequence: 39 givenname: Ming surname: Lim fullname: Lim, Ming organization: Children's Neuroscience, Evelina London Children's Hospital @ Guy's and St Thomas’ NHS Foundation Trust, London, United Kingdom – sequence: 40 givenname: M Isabel surname: Leite fullname: Leite, M Isabel organization: Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom – sequence: 41 givenname: Jacqueline surname: Palace fullname: Palace, Jacqueline organization: Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom – sequence: 42 givenname: Tom surname: Solomon fullname: Solomon, Tom organization: Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom – sequence: 43 givenname: Andreas surname: Lutterotti fullname: Lutterotti, Andreas organization: UniversitätsSpital Zürich, Zürich, Switzerland – sequence: 44 givenname: Kazuo surname: Fujihara fullname: Fujihara, Kazuo organization: Tohoku University Graduate School of Medicine, Sendai, Japan – sequence: 45 givenname: Ichiro orcidid: 0000-0002-2612-8948 surname: Nakashima fullname: Nakashima, Ichiro organization: Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan – sequence: 46 givenname: Jeffrey L surname: Bennett fullname: Bennett, Jeffrey L organization: Departments of Neurology and Ophthalmology, Program in Neuroscience, University of Colorado School of Medicine, Aurora, Colorado, United States – sequence: 47 givenname: Lekha surname: Pandit fullname: Pandit, Lekha organization: Nitte University, Mangaluru, Karnataka, India – sequence: 48 givenname: Tanuja orcidid: 0000-0002-9897-4422 surname: Chitnis fullname: Chitnis, Tanuja organization: Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States – sequence: 49 givenname: Brian G orcidid: 0000-0001-5806-6203 surname: Weinshenker fullname: Weinshenker, Brian G organization: Department of Neurology, Mayo Clinic, Rochester, Minnesota, United States – sequence: 50 givenname: Brigitte surname: Wildemann fullname: Wildemann, Brigitte organization: Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany – sequence: 51 givenname: Douglas Kazutoshi orcidid: 0000-0002-7695-6020 surname: Sato fullname: Sato, Douglas Kazutoshi organization: Hospital das Clinicas Faculty of Medicine, University of São Paulo, São Paulo, Brazil – sequence: 52 givenname: Su-Hyun surname: Kim fullname: Kim, Su-Hyun organization: Research Institute and Hospital of National Cancer Center, Goyang, South Korea – sequence: 53 givenname: Saif surname: Huda fullname: Huda, Saif organization: Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom – sequence: 54 givenname: Ho Jin orcidid: 0000-0002-8672-8419 surname: Kim fullname: Kim, Ho Jin organization: Research Institute and Hospital of National Cancer Center, Goyang, South Korea – sequence: 55 givenname: Markus surname: Reindl fullname: Reindl, Markus organization: Medical University of Innsbruck, Innsbruck, Austria – sequence: 56 givenname: Michael surname: Levy fullname: Levy, Michael organization: Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States – sequence: 57 givenname: Sven surname: Jarius fullname: Jarius, Sven organization: Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany – sequence: 58 givenname: Silvia surname: Tenembaum fullname: Tenembaum, Silvia organization: National Pediatric Hospital Dr. Juan P. Garrahan, Ciudad de Buenos Aires, Argentina – sequence: 59 givenname: Friedemann surname: Paul fullname: Paul, Friedemann organization: Experimental and Clinical Research Center Max Delbrueck Center for Molecular Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany – sequence: 60 givenname: Sean surname: Pittock fullname: Pittock, Sean organization: Department of Neurology, Mayo Clinic, Rochester, Minnesota, United States – sequence: 61 givenname: Romain surname: Marignier fullname: Marignier, Romain organization: Pathologies de la Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, INSERM U1028, CNRS UMR 5292, Lyon 1 University, Center for Research in Neuroscience of Lyon, Lyon, France – sequence: 62 givenname: Anu surname: Jacob fullname: Jacob, Anu email: anu.jacob@thewaltoncentre.nhs.uk organization: Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32629363$$D View this record in MEDLINE/PubMed https://hal.umontpellier.fr/hal-03344233$$DView record in HAL |
| BookMark | eNqFUl1v0zAUjdAQG2O_AAnlER5Sru3YaUBMqiboJhXtgfFsObazuqR2ZzuF_nucZVRQCdUvtq7Px7XPfZmdWGd1lr1GMEGA2PvVZB2EVxMMeKhgTNGz7AxjhAoglJ3sz-X0NLsIYQVpMYpKhl5kpwQzXBNGzjJ-57WIa21j7tr86-28uLmfFyIEJ42IWuXKBOeV9vlPE5e5N7H_Zdai-ZDPbG5s1N6KaJwVXR5ir3aDCsIo36RqEg2vsuet6IK-eNrPs-9fPt9dXReL2_nN1WxRSAYQC0EZrhjFtG4lVdCoqhYCkMCAUKWaEhpoKKFNWVcEayQYA8ZoqViNCZQtIufZ5ai76Zu1VjJ5e9HxjU_N-h13wvB_b6xZ8nu35dW0pgRYEng3CiwPaNezBR9qQEhZYkK2g9nbJzPvHnodIl-bIHXXCatdHzgu098jIKxK0Dd_97VX_pNAApARIL0Lwet2D0HAh6j5ij9GzYeo-Rh1YtUHLGniYxDpcaY7wv00cnXKY2u050GmrKRWxmsZuXLmCP_ygC87Y40U3Q-902Hl-jQTXeCIB8yBfxsGcZhDDAQIrqZJ4OP_BY7a_wbCleuS |
| CitedBy_id | crossref_primary_10_1016_j_ejpn_2024_07_002 crossref_primary_10_1038_s41582_024_01014_1 crossref_primary_10_1016_j_jns_2021_120044 crossref_primary_10_1038_s41582_021_00568_8 crossref_primary_10_3389_fneur_2020_00778 crossref_primary_10_1016_j_autrev_2024_103693 crossref_primary_10_1016_j_msard_2022_103525 crossref_primary_10_1038_s41433_024_03108_y crossref_primary_10_1177_13524585211057512 crossref_primary_10_1177_13524585251367343 crossref_primary_10_1016_j_msard_2022_103926 crossref_primary_10_1212_NXI_0000000000001100 crossref_primary_10_1016_S1474_4422_21_00218_0 crossref_primary_10_1136_jnnp_2024_334764 crossref_primary_10_1177_13524585221090737 crossref_primary_10_1177_20552173241301011 crossref_primary_10_1097_WNO_0000000000001684 crossref_primary_10_1007_s00415_023_11737_8 crossref_primary_10_1111_cen3_12630 crossref_primary_10_1016_j_msard_2023_104571 crossref_primary_10_1212_NXI_0000000000200268 crossref_primary_10_2147_ITT_S287652 crossref_primary_10_1016_j_msard_2022_104442 crossref_primary_10_1016_j_jneuroim_2025_578522 crossref_primary_10_3389_fnins_2023_1014071 crossref_primary_10_1002_acn3_51759 crossref_primary_10_1016_j_pharmthera_2022_108180 crossref_primary_10_1080_14728214_2020_1803828 crossref_primary_10_1007_s40120_023_00481_w crossref_primary_10_1038_s41573_020_00092_2 crossref_primary_10_3389_fneur_2021_673339 crossref_primary_10_1080_14728214_2021_1919082 crossref_primary_10_3389_fimmu_2023_1121705 crossref_primary_10_1136_bjophthalmol_2020_318769 crossref_primary_10_1080_14737175_2024_2385941 crossref_primary_10_1212_NXI_0000000000000925 crossref_primary_10_1055_a_1928_5117 crossref_primary_10_1212_CON_0000000000001127 crossref_primary_10_1080_1744666X_2022_2105205 crossref_primary_10_1016_j_jneuroim_2022_577812 crossref_primary_10_1016_j_neurol_2025_04_012 crossref_primary_10_1002_ana_26226 crossref_primary_10_3389_fimmu_2025_1530977 crossref_primary_10_1186_s12883_022_02612_6 crossref_primary_10_1136_jnnp_2020_324422 crossref_primary_10_1038_s41433_023_02477_0 crossref_primary_10_1016_j_msard_2024_105729 crossref_primary_10_3389_fimmu_2025_1594960 crossref_primary_10_3389_fneur_2021_662353 crossref_primary_10_1007_s10384_022_00932_1 crossref_primary_10_1212_WNL_0000000000201260 crossref_primary_10_1111_cen3_12771 crossref_primary_10_2217_nmt_2020_0046 crossref_primary_10_1111_cei_13641 crossref_primary_10_1016_j_msard_2025_106548 crossref_primary_10_4103_sjopt_sjopt_102_23 crossref_primary_10_1016_j_msard_2021_103310 crossref_primary_10_1007_s00415_020_10236_4 crossref_primary_10_1212_NXI_0000000000001110 crossref_primary_10_1111_ene_15684 crossref_primary_10_1038_s41572_020_0214_9 crossref_primary_10_1111_imr_13405 crossref_primary_10_1016_j_jns_2020_117225 crossref_primary_10_1016_j_nerep_2023_100183 crossref_primary_10_1016_j_intimp_2022_109004 crossref_primary_10_1097_WCO_0000000000001128 crossref_primary_10_1007_s00415_022_11194_9 crossref_primary_10_1055_a_1918_1824 crossref_primary_10_3389_fimmu_2022_832084 crossref_primary_10_3390_ijms241713368 crossref_primary_10_3390_ijms26178538 crossref_primary_10_3389_fnins_2023_1205065 crossref_primary_10_1016_j_msard_2021_103044 crossref_primary_10_7759_cureus_52374 crossref_primary_10_1212_NXI_0000000000000977 crossref_primary_10_1111_cns_14608 crossref_primary_10_1212_cont_0000000000001560 crossref_primary_10_22379_anc_v40i2_1837 crossref_primary_10_1016_S1474_4422_20_30432_4 crossref_primary_10_7759_cureus_68563 crossref_primary_10_1136_jnnp_2022_330086 crossref_primary_10_1016_j_msard_2023_104787 crossref_primary_10_1016_j_msard_2025_106602 crossref_primary_10_1016_j_jneuroim_2025_578686 crossref_primary_10_1016_j_jneuroim_2021_577750 crossref_primary_10_1007_s11940_021_00672_6 crossref_primary_10_1016_j_msard_2022_104128 crossref_primary_10_3389_fimmu_2023_1129906 crossref_primary_10_1016_j_msard_2024_105859 crossref_primary_10_1212_NXI_0000000000001134 crossref_primary_10_3389_fimmu_2024_1510097 crossref_primary_10_1007_s00455_021_10338_9 crossref_primary_10_1136_jnnp_2024_333464 crossref_primary_10_1097_WNO_0000000000001772 crossref_primary_10_1177_13524585241226830 crossref_primary_10_3389_fneur_2023_1102353 crossref_primary_10_1016_j_jns_2020_117088 crossref_primary_10_1080_14712598_2025_2491603 crossref_primary_10_1007_s13311_022_01196_w crossref_primary_10_1111_ene_16445 crossref_primary_10_1016_j_msard_2021_103229 crossref_primary_10_1055_s_0042_1760100 crossref_primary_10_1097_WCO_0000000000001052 crossref_primary_10_3390_ijms23179769 crossref_primary_10_1016_j_ejpn_2020_10_005 crossref_primary_10_1007_s00115_021_01106_z crossref_primary_10_3389_fneur_2023_1137998 crossref_primary_10_1212_NXI_0000000000000919 crossref_primary_10_1016_j_msard_2023_104760 crossref_primary_10_1016_j_msard_2021_103356 crossref_primary_10_1016_j_pediatrneurol_2023_12_018 crossref_primary_10_2147_ITT_S255722 crossref_primary_10_1016_j_conb_2022_102643 crossref_primary_10_3389_fimmu_2021_686466 crossref_primary_10_1111_cen3_12627 crossref_primary_10_3389_fneur_2022_885218 crossref_primary_10_1016_j_spen_2023_101056 crossref_primary_10_1177_17562864211054157 crossref_primary_10_3389_fimmu_2021_671425 crossref_primary_10_1016_j_msard_2025_106460 crossref_primary_10_1111_cen3_12623 crossref_primary_10_3389_fimmu_2022_953993 crossref_primary_10_1007_s40278_020_81615_5 |
| Cites_doi | 10.1186/s12974-016-0718-0 10.1001/jamaneurol.2017.4601 10.1002/ana.25291 10.1002/ana.21363 10.1056/NEJMoa1601277 10.1212/01.WNL.0000159399.81861.D5 10.1016/j.msard.2018.11.012 10.1001/jamaneurol.2013.5699 10.1001/jamaneurol.2013.3071 10.1016/S1474-4422(12)70310-1 10.1056/NEJMoa1606468 10.1056/NEJMoa0706383 10.1001/archneurol.2011.154 10.1212/NXI.0000000000000061 10.1136/jnnp-2017-316880 10.1016/j.msard.2012.06.002 10.1001/jamaneurol.2016.1637 10.1016/j.jocn.2010.12.011 10.1016/j.jns.2012.02.017 10.1212/WNL.0000000000005560 10.1001/jamaneurol.2015.1276 10.1007/s00415-017-8596-7 10.1212/WNL.0000000000001179 10.1038/nm1488 10.1186/1742-2094-8-184 10.1001/archneur.65.11.noc80069 10.1212/WNL.0b013e3182152881 10.1016/j.jns.2017.01.025 10.1093/brain/awx276 10.1212/WNL.0b013e31826aac4e 10.1001/jamaneurol.2018.1814 10.1177/1352458515594042 10.1177/1352458506070820 10.1212/WNL.0000000000007312 10.1212/NXI.0000000000000625 10.1111/ene.13602 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier B.V. Elsevier B.V. Copyright © 2020 Elsevier B.V. All rights reserved. licence_http://creativecommons.org/publicdomain/zero |
| Copyright_xml | – notice: 2020 Elsevier B.V. – notice: Elsevier B.V. – notice: Copyright © 2020 Elsevier B.V. All rights reserved. – notice: licence_http://creativecommons.org/publicdomain/zero |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 1XC 5PM |
| DOI | 10.1016/j.msard.2020.102251 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2211-0356 2211-0348 |
| EndPage | 102251 |
| ExternalDocumentID | PMC7895306 oai:HAL:hal-03344233v1 32629363 10_1016_j_msard_2020_102251 S2211034820303278 1_s2_0_S2211034820303278 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NEI NIH HHS grantid: R01 EY022936 – fundername: Department of Health grantid: IS-HPU-1112-10117 – fundername: Medical Research Council grantid: MR/T024437/1 |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1P~ 1~. 1~5 4.4 457 4G. 53G 5VS 7-5 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABGSF ABJNI ABMAC ABMZM ABTEW ABUDA ABWVN ABXDB ACDAQ ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV EBS EFJIC EFKBS EFLBG EJD FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MO0 MOBAO O-L O9- OAUVE OP~ P-8 P-9 PC. Q38 ROL SDF SEL SPCBC SSH SSN SSU SSZ T5K Z5R ~G- ~HD AACTN AFKWA AJOXV AMFUW RIG AADPK AAIAV ABLVK ABYKQ AJBFU DOVZS LCYCR AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 1XC 5PM |
| ID | FETCH-LOGICAL-c600t-a562765259fc5d0bd79aa01a20117db40b0b535b49732e1a6606654d692304f13 |
| ISICitedReferencesCount | 122 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000599869900010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2211-0348 2211-0356 |
| IngestDate | Tue Sep 30 16:25:14 EDT 2025 Sun Nov 23 06:21:37 EST 2025 Sun Sep 28 12:24:47 EDT 2025 Mon Jul 21 06:06:36 EDT 2025 Wed Nov 05 20:41:46 EST 2025 Tue Nov 18 21:45:45 EST 2025 Fri Feb 23 02:45:02 EST 2024 Tue Feb 25 20:07:11 EST 2025 Tue Oct 14 19:31:07 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Keywords | Rituximab Neuromyelitis optica Myelin oligodendrocyte glycoprotein MOG Optic neuritis |
| Language | English |
| License | Copyright © 2020 Elsevier B.V. All rights reserved. licence_http://creativecommons.org/publicdomain/zero/: http://creativecommons.org/publicdomain/zero |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c600t-a562765259fc5d0bd79aa01a20117db40b0b535b49732e1a6606654d692304f13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PMCID: PMC7895306 Daniel H Whittam: Methodology, investigation, data curation, formal analysis, writing – original draft. Alvaro Cobo-Calvo: Investigation, writing – review & editing. A Sebastian Lopez-Chiriboga: Investigation, writing – review & editing. Santiago Pardo: Investigation. Matthew Gornall: Formal analysis. Silvia Cicconi: Formal analysis. Alexander Brandt: Investigation. Klaus Berek: Investigation. Thomas Berger: Investigation. Ilijas Jelcic: Investigation. Grace Gombolay: Investigation, writing – review & editing. Luana Micheli Oliveira: Investigation. Dagoberto Callegaro: Investigation. Kimihiko Kaneko: Investigation. Tatsuro Misu: Investigation. Marco Capobianco: Investigation, writing – review & editing. Emily Gibbons: Investigation. Venkatraman Karthikeayan: Investigation. Bruno Brochet: Investigation. Bertrand Audoin: Investigation. Guillaume Mathey: Investigation. David Laplaud: Investigation. Eric Thouvenot: Investigation. Mikaël Cohen: Investigation. Ayman Tourbah: Investigation. Elisabeth Maillart: Investigation. Jonathan Ciron: Investigation. Romain Deschamps MD: Investigation. Damien Biotti: Investigation. Kevin Rostasy: Investigation, writing – review & editing. Rinze Neuteboom: Investigation. Cheryl Hemingway: Investigation, writing – review & editing. Rob Forsyth: Investigation. Marcelo Matiello: Investigation. Stewart Webb: Investigation. David Hunt: Investigation. Katy Murray: Investigation, writing – review & editing. Yael Hacohen: Investigation, data curation, writing – review & editing. Ming Lim: Investigation, writing – review & editing, M Isabel Leite: Investigation, writing – review & editing. Jacqueline Palace: Investigation, writing – review & editing. Tom Solomon: Investigation, supervision, writing – review & editing. Andreas Lutterotti: Investigation, writing – review & editing. Kazuo Fujihara: Investigation, writing – review & editing. Ichiro Nakashima: Investigation, writing – review & editing. Jeffrey L. Bennett: Investigation, writing – review & editing. Lekha Pandit: Investigation, writing – review & editing. Tanuja Chitnis: Investigation, writing – review & editing. Brian G Weinshenker: Investigation, writing – review & editing. Brigitte Wildemann: Investigation, writing – review & editing. Douglas Kazutoshi Sato: Investigation, writing – review & editing. Su-Hyun Kim: Investigation, writing – review & editing. Saif Huda: Investigation, writing – review & editing. Ho Jin Kim: Investigation, writing – review & editing. Markus Reindl: Investigation, writing – review & editing. Michael Levy: Investigation, writing – review & editing. Sven Jarius: Investigation, writing – review & editing. Silvia Tenembaum: Investigation, writing – review & editing. Friedemann Paul: Investigation, writing – review & editing. Sean Pittock: Investigation, writing – review & editing. Romain Marignier: Investigation, resources, writing – review & editing. Anu Jacob: Conceptualization, methodology, resources, supervision, writing – review & editing. CRediT author statement |
| ORCID | 0000-0002-7311-2578 0000-0001-5806-6203 0000-0003-2755-2043 0000-0002-3386-6308 0000-0003-3824-2796 0000-0003-0569-629X 0000-0002-7695-6020 0000-0002-2612-8948 0000-0002-3985-1297 0000-0002-9430-8190 0000-0002-8672-8419 0000-0002-9897-4422 0000-0002-9860-7657 0000-0001-6113-6938 0000-0002-5967-2800 0000-0002-7969-8346 0000-0001-8671-7747 |
| OpenAccessLink | http://www.msard-journal.com/article/S2211034820303278/pdf |
| PMID | 32629363 |
| PQID | 2421110367 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7895306 hal_primary_oai_HAL_hal_03344233v1 proquest_miscellaneous_2421110367 pubmed_primary_32629363 crossref_primary_10_1016_j_msard_2020_102251 crossref_citationtrail_10_1016_j_msard_2020_102251 elsevier_sciencedirect_doi_10_1016_j_msard_2020_102251 elsevier_clinicalkeyesjournals_1_s2_0_S2211034820303278 elsevier_clinicalkey_doi_10_1016_j_msard_2020_102251 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-09-01 |
| PublicationDateYYYYMMDD | 2020-09-01 |
| PublicationDate_xml | – month: 09 year: 2020 text: 2020-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Multiple sclerosis and related disorders |
| PublicationTitleAlternate | Mult Scler Relat Disord |
| PublicationYear | 2020 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Kim, Jeong, Hyun (bib0021) 2015; 72 Nakashima, Takahashi, Cree (bib0031) 2011; 18 Damato, Evoli, Iorio (bib0023) 2016; 73 Jarius, Ruprecht, Kleiter (bib0007) 2016; 13 Ramanathan, Mohammad, Tantsis (bib0010) 2018; 89 Kitley, Woodhall, Waters (bib0003) 2012; 79 Pellkofer, Krumbholz, Berthele (bib0017) 2011; 76 Cobo-Calvo, Ruiz, Maillart (bib0006) 2018; 90 Hachohen, Wong, Lechner (bib0009) 2018; 75 Jacob, Weinshenker, Violich (bib0016) 2008; 65 Kim, Kim, Li (bib0019) 2011; 68 Cohen, Romero, Bas (bib0024) 2017; 373 Mader, Gredler, Schanda (bib0002) 2011; 8 Kimbrough, Fujihara, Jacob (bib0026) 2012; 1 Lindsey, Meulmester, Brod (bib0025) 2012; 317 Radaelli, Moiola, Sangalli (bib0022) 2016; 22 Martínez-Yélamos, Martínez-Yélamos, Martín Ozaeta, Casado, Camona, Arbizu (bib0027) 2006; 16 Hayward-Könnecke, Reindl, Martin, Schippling (bib0036) 2019; 92 Perumal, Kister, Howard (bib0030) 2015; 2 Hamid, Whittam, Mutch (bib0008) 2017; 264 Kim, Huh, Lee (bib0020) 2013; 70 Montalban, Hauser, Kappos (bib0014) 2017; 376 Bar-Or, Calabresi, Arnold (bib0011) 2008; 63 Lopez-Chiriboga, Majed, Fryer (bib0004) 2018; 75 Ringelstein, Kleiter, Rommer (bib0037) 2019 Mealy, Wingerchuk, Palace (bib0018) 2014; 71 Titulaer, McCracken, Gabilondo (bib0028) 2013; 12 Hauser, Bar-Or, Comi (bib0013) 2017; 376 Novi, Gastaldi, Franciotta (bib0035) 2019; 27 Winklmeier, Schlüter, Spadaro (bib0033) 2019; 6 Wong, Hacohen, Armangue (bib0034) 2018; 25 Cree, Lamb, Morgan (bib0015) 2005; 64 Hauser, Waubant, Arnold (bib0012) 2008; 358 Jurynczyk, Messina, Woodhall (bib0005) 2017; 140 Deiva, Absoud, Hemingway (bib0029) 2015; 84 Spadaro, Winklmeier, Beltrán (bib0032) 2018; 84 O'Connor, McLaughlin, De Jager (bib0001) 2007; 13 Kimbrough (10.1016/j.msard.2020.102251_bib0026) 2012; 1 Hauser (10.1016/j.msard.2020.102251_bib0013) 2017; 376 Kim (10.1016/j.msard.2020.102251_bib0021) 2015; 72 Kim (10.1016/j.msard.2020.102251_bib0020) 2013; 70 O'Connor (10.1016/j.msard.2020.102251_bib0001) 2007; 13 Cree (10.1016/j.msard.2020.102251_bib0015) 2005; 64 Mealy (10.1016/j.msard.2020.102251_bib0018) 2014; 71 Novi (10.1016/j.msard.2020.102251_bib0035) 2019; 27 Bar-Or (10.1016/j.msard.2020.102251_bib0011) 2008; 63 Hayward-Könnecke (10.1016/j.msard.2020.102251_bib0036) 2019; 92 Martínez-Yélamos (10.1016/j.msard.2020.102251_bib0027) 2006; 16 Spadaro (10.1016/j.msard.2020.102251_bib0032) 2018; 84 Hachohen (10.1016/j.msard.2020.102251_bib0009) 2018; 75 Ringelstein (10.1016/j.msard.2020.102251_bib0037) 2019 Jarius (10.1016/j.msard.2020.102251_bib0007) 2016; 13 Kim (10.1016/j.msard.2020.102251_bib0019) 2011; 68 Jacob (10.1016/j.msard.2020.102251_bib0016) 2008; 65 Hauser (10.1016/j.msard.2020.102251_bib0012) 2008; 358 Titulaer (10.1016/j.msard.2020.102251_bib0028) 2013; 12 Kitley (10.1016/j.msard.2020.102251_bib0003) 2012; 79 Montalban (10.1016/j.msard.2020.102251_bib0014) 2017; 376 Mader (10.1016/j.msard.2020.102251_bib0002) 2011; 8 Cohen (10.1016/j.msard.2020.102251_bib0024) 2017; 373 Lindsey (10.1016/j.msard.2020.102251_bib0025) 2012; 317 Damato (10.1016/j.msard.2020.102251_bib0023) 2016; 73 Pellkofer (10.1016/j.msard.2020.102251_bib0017) 2011; 76 Radaelli (10.1016/j.msard.2020.102251_bib0022) 2016; 22 Hamid (10.1016/j.msard.2020.102251_bib0008) 2017; 264 Deiva (10.1016/j.msard.2020.102251_bib0029) 2015; 84 Perumal (10.1016/j.msard.2020.102251_bib0030) 2015; 2 Ramanathan (10.1016/j.msard.2020.102251_bib0010) 2018; 89 Winklmeier (10.1016/j.msard.2020.102251_bib0033) 2019; 6 Lopez-Chiriboga (10.1016/j.msard.2020.102251_bib0004) 2018; 75 Nakashima (10.1016/j.msard.2020.102251_bib0031) 2011; 18 Wong (10.1016/j.msard.2020.102251_bib0034) 2018; 25 Jurynczyk (10.1016/j.msard.2020.102251_bib0005) 2017; 140 Cobo-Calvo (10.1016/j.msard.2020.102251_bib0006) 2018; 90 |
| References_xml | – volume: 84 start-page: 315 year: 2018 end-page: 318 ident: bib0032 article-title: Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein publication-title: Ann Neurol – volume: 376 start-page: 209 year: 2017 end-page: 220 ident: bib0014 article-title: Ocrelizumab versus placebo in primary progressive multiple sclerosis publication-title: N Engl J Med – volume: 89 start-page: 127 year: 2018 end-page: 137 ident: bib0010 article-title: Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination publication-title: J Neurol Neurosurg Psychiatry – volume: 25 start-page: 782 year: 2018 end-page: 786 ident: bib0034 article-title: Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome publication-title: Eur J Neurol – volume: 8 start-page: 184 year: 2011 ident: bib0002 article-title: Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders publication-title: J Neuroinflammation – volume: 63 start-page: 395 year: 2008 end-page: 400 ident: bib0011 article-title: Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial publication-title: Ann Neurol – volume: 65 start-page: 1443 year: 2008 end-page: 1448 ident: bib0016 article-title: Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients publication-title: Arch Neurol – volume: 64 start-page: 1270 year: 2005 end-page: 1272 ident: bib0015 article-title: An open label study of the effects of rituximab in neuromyelitis optica publication-title: Neurology – volume: 1 start-page: 180 year: 2012 end-page: 187 ident: bib0026 article-title: Treatment of neuromyelitis optica: review and recommendations publication-title: Mult Scler Relat Disord – volume: 75 start-page: 1355 year: 2018 end-page: 1363 ident: bib0004 article-title: Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders publication-title: JAMA Neurol – volume: 22 start-page: 511 year: 2016 end-page: 519 ident: bib0022 article-title: Neuromyelitis optica spectrum disorders: Long-term safety and efficacy of rituximab in Caucasian patients publication-title: Mult Scler – volume: 373 start-page: 335 year: 2017 end-page: 338 ident: bib0024 article-title: Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study publication-title: J Neurol Sci – volume: 75 start-page: 478 year: 2018 end-page: 487 ident: bib0009 article-title: Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease publication-title: JAMA Neurol – volume: 84 start-page: 341 year: 2015 end-page: 349 ident: bib0029 article-title: UK Childhood Inflammatory Demyelination (UK-CID) Study and French Kidbiosep Study. Acute idiopathic transverse myelitis in children publication-title: Neurology – volume: 76 start-page: 1310 year: 2011 end-page: 1315 ident: bib0017 article-title: Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab publication-title: Neurology – volume: 68 start-page: 1412 year: 2011 end-page: 1419 ident: bib0019 article-title: Repeated treatment with rituximab based on the assessment of peripheral circulating memory B-cells in patients with relapsing neuromyelitis optica over 2 years publication-title: Arch Neurol – volume: 16 start-page: 826 year: 2006 end-page: 829 ident: bib0027 article-title: Regression to the mean in multiple sclerosis publication-title: Mult Scler – volume: 27 start-page: 312 year: 2019 end-page: 314 ident: bib0035 article-title: Tocilizumab in MOG-antibody spectrum disorder: a case report publication-title: Mult Scler Relat Disord – volume: 90 start-page: e1858 year: 2018 end-page: e1869 ident: bib0006 article-title: Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study publication-title: Neurology – volume: 12 start-page: 157 year: 2013 end-page: 165 ident: bib0028 article-title: Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis publication-title: Lancet Neurol – volume: 13 start-page: 280 year: 2016 ident: bib0007 article-title: MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome publication-title: J Neuroinflammation – volume: 264 start-page: 2088 year: 2017 end-page: 2094 ident: bib0008 article-title: What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients publication-title: J Neurol – volume: 358 start-page: 676 year: 2008 end-page: 688 ident: bib0012 article-title: B-cell depletion with rituximab in relapsing–remitting multiple sclerosis publication-title: N Engl J Med – volume: 6 start-page: e625 year: 2019 ident: bib0033 article-title: Identification of circulating MOG-specific B cells in patients with MOG antibodies publication-title: Neurol Neuroimmunol Neuroinflamm – volume: 73 start-page: 1342 year: 2016 end-page: 1348 ident: bib0023 article-title: Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis publication-title: JAMA Neurol – volume: 71 start-page: 324 year: 2014 end-page: 330 ident: bib0018 article-title: Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy publication-title: JAMA Neurol – volume: 317 start-page: 103 year: 2012 end-page: 105 ident: bib0025 article-title: Variable results after rituximab in neuromyelitis optica publication-title: J Neurol Sci – volume: 140 start-page: 3128 year: 2017 end-page: 3138 ident: bib0005 article-title: Clinical presentation and prognosis in MOG-antibody disease: A UK study publication-title: Brain – volume: 2 start-page: e61 year: 2015 ident: bib0030 article-title: Disease exacerbation after rituximab induction in neuromyelitis optica publication-title: Neurol Neuroimmunol Neuroinflamm – volume: 79 start-page: 1273 year: 2012 end-page: 1277 ident: bib0003 article-title: Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype publication-title: Neurology – volume: 70 start-page: 1110 year: 2013 end-page: 1117 ident: bib0020 article-title: A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder publication-title: JAMA Neurol – volume: 92 start-page: 765 year: 2019 end-page: 767 ident: bib0036 article-title: Tocilizumab in severe recurrent anti-MOG-associated optic neuritis publication-title: Neurology – volume: 18 start-page: 997 year: 2011 end-page: 998 ident: bib0031 article-title: Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels publication-title: J Clin Neurosci – volume: 13 start-page: 211 year: 2007 end-page: 217 ident: bib0001 article-title: Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein publication-title: Nat Med – volume: 72 start-page: 989 year: 2015 end-page: 995 ident: bib0021 article-title: Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: Influence of FCGR3A polymorphisms on the therapeutic response to rituximab publication-title: JAMA Neurol – volume: 376 start-page: 221 year: 2017 end-page: 234 ident: bib0013 article-title: Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis publication-title: N Engl J Med – year: 2019 ident: bib0037 article-title: Long-term interleukin-6-receptor blockade in neuromyelitis optica spectrum disorder and MOG associated encephalomyelitis (P1344). Poster presented at: 35 – volume: 13 start-page: 280 issue: 1 year: 2016 ident: 10.1016/j.msard.2020.102251_bib0007 article-title: MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome publication-title: J Neuroinflammation doi: 10.1186/s12974-016-0718-0 – volume: 75 start-page: 478 issue: 4 year: 2018 ident: 10.1016/j.msard.2020.102251_bib0009 article-title: Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2017.4601 – volume: 84 start-page: 315 issue: 2 year: 2018 ident: 10.1016/j.msard.2020.102251_bib0032 article-title: Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein publication-title: Ann Neurol doi: 10.1002/ana.25291 – volume: 63 start-page: 395 issue: 3 year: 2008 ident: 10.1016/j.msard.2020.102251_bib0011 article-title: Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial publication-title: Ann Neurol doi: 10.1002/ana.21363 – volume: 376 start-page: 221 issue: 3 year: 2017 ident: 10.1016/j.msard.2020.102251_bib0013 article-title: Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1601277 – volume: 64 start-page: 1270 issue: 7 year: 2005 ident: 10.1016/j.msard.2020.102251_bib0015 article-title: An open label study of the effects of rituximab in neuromyelitis optica publication-title: Neurology doi: 10.1212/01.WNL.0000159399.81861.D5 – volume: 27 start-page: 312 year: 2019 ident: 10.1016/j.msard.2020.102251_bib0035 article-title: Tocilizumab in MOG-antibody spectrum disorder: a case report publication-title: Mult Scler Relat Disord doi: 10.1016/j.msard.2018.11.012 – volume: 71 start-page: 324 year: 2014 ident: 10.1016/j.msard.2020.102251_bib0018 article-title: Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2013.5699 – volume: 70 start-page: 1110 year: 2013 ident: 10.1016/j.msard.2020.102251_bib0020 article-title: A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2013.3071 – volume: 12 start-page: 157 issue: 2 year: 2013 ident: 10.1016/j.msard.2020.102251_bib0028 article-title: Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis publication-title: Lancet Neurol doi: 10.1016/S1474-4422(12)70310-1 – volume: 376 start-page: 209 issue: 3 year: 2017 ident: 10.1016/j.msard.2020.102251_bib0014 article-title: Ocrelizumab versus placebo in primary progressive multiple sclerosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1606468 – volume: 358 start-page: 676 issue: 7 year: 2008 ident: 10.1016/j.msard.2020.102251_bib0012 article-title: B-cell depletion with rituximab in relapsing–remitting multiple sclerosis publication-title: N Engl J Med doi: 10.1056/NEJMoa0706383 – volume: 68 start-page: 1412 year: 2011 ident: 10.1016/j.msard.2020.102251_bib0019 article-title: Repeated treatment with rituximab based on the assessment of peripheral circulating memory B-cells in patients with relapsing neuromyelitis optica over 2 years publication-title: Arch Neurol doi: 10.1001/archneurol.2011.154 – volume: 2 start-page: e61 issue: 1 year: 2015 ident: 10.1016/j.msard.2020.102251_bib0030 article-title: Disease exacerbation after rituximab induction in neuromyelitis optica publication-title: Neurol Neuroimmunol Neuroinflamm doi: 10.1212/NXI.0000000000000061 – volume: 89 start-page: 127 issue: 2 year: 2018 ident: 10.1016/j.msard.2020.102251_bib0010 article-title: Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2017-316880 – volume: 1 start-page: 180 issue: 4 year: 2012 ident: 10.1016/j.msard.2020.102251_bib0026 article-title: Treatment of neuromyelitis optica: review and recommendations publication-title: Mult Scler Relat Disord doi: 10.1016/j.msard.2012.06.002 – volume: 73 start-page: 1342 issue: 11 year: 2016 ident: 10.1016/j.msard.2020.102251_bib0023 article-title: Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2016.1637 – volume: 18 start-page: 997 issue: 7 year: 2011 ident: 10.1016/j.msard.2020.102251_bib0031 article-title: Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels publication-title: J Clin Neurosci doi: 10.1016/j.jocn.2010.12.011 – volume: 317 start-page: 103 issue: 1-2 year: 2012 ident: 10.1016/j.msard.2020.102251_bib0025 article-title: Variable results after rituximab in neuromyelitis optica publication-title: J Neurol Sci doi: 10.1016/j.jns.2012.02.017 – volume: 90 start-page: e1858 issue: 21 year: 2018 ident: 10.1016/j.msard.2020.102251_bib0006 article-title: Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study publication-title: Neurology doi: 10.1212/WNL.0000000000005560 – volume: 72 start-page: 989 issue: 9 year: 2015 ident: 10.1016/j.msard.2020.102251_bib0021 article-title: Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: Influence of FCGR3A polymorphisms on the therapeutic response to rituximab publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2015.1276 – volume: 264 start-page: 2088 issue: 10 year: 2017 ident: 10.1016/j.msard.2020.102251_bib0008 article-title: What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients publication-title: J Neurol doi: 10.1007/s00415-017-8596-7 – volume: 84 start-page: 341 issue: 4 year: 2015 ident: 10.1016/j.msard.2020.102251_bib0029 article-title: UK Childhood Inflammatory Demyelination (UK-CID) Study and French Kidbiosep Study. Acute idiopathic transverse myelitis in children publication-title: Neurology doi: 10.1212/WNL.0000000000001179 – year: 2019 ident: 10.1016/j.msard.2020.102251_bib0037 – volume: 13 start-page: 211 issue: 2 year: 2007 ident: 10.1016/j.msard.2020.102251_bib0001 article-title: Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein publication-title: Nat Med doi: 10.1038/nm1488 – volume: 8 start-page: 184 year: 2011 ident: 10.1016/j.msard.2020.102251_bib0002 article-title: Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders publication-title: J Neuroinflammation doi: 10.1186/1742-2094-8-184 – volume: 65 start-page: 1443 issue: 11 year: 2008 ident: 10.1016/j.msard.2020.102251_bib0016 article-title: Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients publication-title: Arch Neurol doi: 10.1001/archneur.65.11.noc80069 – volume: 76 start-page: 1310 year: 2011 ident: 10.1016/j.msard.2020.102251_bib0017 article-title: Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab publication-title: Neurology doi: 10.1212/WNL.0b013e3182152881 – volume: 373 start-page: 335 year: 2017 ident: 10.1016/j.msard.2020.102251_bib0024 article-title: Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study publication-title: J Neurol Sci doi: 10.1016/j.jns.2017.01.025 – volume: 140 start-page: 3128 issue: 12 year: 2017 ident: 10.1016/j.msard.2020.102251_bib0005 article-title: Clinical presentation and prognosis in MOG-antibody disease: A UK study publication-title: Brain doi: 10.1093/brain/awx276 – volume: 79 start-page: 1273 issue: 12 year: 2012 ident: 10.1016/j.msard.2020.102251_bib0003 article-title: Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype publication-title: Neurology doi: 10.1212/WNL.0b013e31826aac4e – volume: 75 start-page: 1355 issue: 11 year: 2018 ident: 10.1016/j.msard.2020.102251_bib0004 article-title: Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2018.1814 – volume: 22 start-page: 511 issue: 4 year: 2016 ident: 10.1016/j.msard.2020.102251_bib0022 article-title: Neuromyelitis optica spectrum disorders: Long-term safety and efficacy of rituximab in Caucasian patients publication-title: Mult Scler doi: 10.1177/1352458515594042 – volume: 16 start-page: 826 issue: 6 year: 2006 ident: 10.1016/j.msard.2020.102251_bib0027 article-title: Regression to the mean in multiple sclerosis publication-title: Mult Scler doi: 10.1177/1352458506070820 – volume: 92 start-page: 765 issue: 16 year: 2019 ident: 10.1016/j.msard.2020.102251_bib0036 article-title: Tocilizumab in severe recurrent anti-MOG-associated optic neuritis publication-title: Neurology doi: 10.1212/WNL.0000000000007312 – volume: 6 start-page: e625 year: 2019 ident: 10.1016/j.msard.2020.102251_bib0033 article-title: Identification of circulating MOG-specific B cells in patients with MOG antibodies publication-title: Neurol Neuroimmunol Neuroinflamm doi: 10.1212/NXI.0000000000000625 – volume: 25 start-page: 782 issue: 5 year: 2018 ident: 10.1016/j.msard.2020.102251_bib0034 article-title: Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome publication-title: Eur J Neurol doi: 10.1111/ene.13602 |
| SSID | ssj0000651461 |
| Score | 2.5293443 |
| Snippet | •Largest study of rituximab in MOG-IgG-associated disorder, includes both adults and children.•Rituximab reduced relapse rates in MOG-IgG-associated disorder... Highlights•Largest study of rituximab in MOG-IgG-associated disorder, includes both adults and children. •Rituximab reduced relapse rates in MOG-IgG-associated... To assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder... Objective: to assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated... |
| SourceID | pubmedcentral hal proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 102251 |
| SubjectTerms | Autoantibodies Child Human health and pathology Humans Immunoglobulin G Life Sciences MOG Myelin oligodendrocyte glycoprotein Neurology Neuromyelitis Optica Neurons and Cognition Optic neuritis Pediatrics Prospective Studies Retrospective Studies Rituximab Rituximab - therapeutic use Sensory Organs |
| Title | Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2211034820303278 https://www.clinicalkey.es/playcontent/1-s2.0-S2211034820303278 https://dx.doi.org/10.1016/j.msard.2020.102251 https://www.ncbi.nlm.nih.gov/pubmed/32629363 https://www.proquest.com/docview/2421110367 https://hal.umontpellier.fr/hal-03344233 https://pubmed.ncbi.nlm.nih.gov/PMC7895306 |
| Volume | 44 |
| WOSCitedRecordID | wos000599869900010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 2211-0356 dateEnd: 20210531 omitProxy: false ssIdentifier: ssj0000651461 issn: 2211-0348 databaseCode: AIEXJ dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6DSFeEJ-jfEwB8UimfDvhrSrbWuhKpQ2pb5aTJmumLqmatKr46_jTuIvtNKUwxgMvVuXEsZP71b473_1MyPvI81w7QT7tELcZuZ_ovgsFUo_7jotafpUoPKDDoT8eB6NW64fKhVnNaJb563Uw_6-ihjoQNqbO_oO464dCBfwGoUMJYofyboKvQ8cxuuXrmd6_OtO5lAKolxPJtylcsIu0XK7TGx5WWc9ZRR-x8RAWinLatExFwVo09dlzFY9YwChgwU0F5XOVIdPoq9jM_WlZCgyK5PZ6DyQPc73LZyuZdrPii7wOFsrn8Xe9O00XaSgdwRwmOViAywa4R4D1XDi5M6i_ypsODbBeVcSW9LJJlWAzEVoWunFtV1JmN-sES6eayQWT5M6iIPwT18c3BQzkGLtEwgpLEt1uUXD3Ohds9OmUDfrDL9tXG3GLvc4AyimfwQBsB_RRewX294FF3QDm1YNO_2T8ufbzgYqHR6fjGYfqNRT5VRVmuDOoPylIe1OM1N01g36N5m2oR5ePyENp12gdgcfHpBVnT8j9cxm58ZSwGpZanmi7sNQUVDSEpVbD8qPGM20LlFoFSnwKgFJToHxGvp2eXHZ7ujzcQ49Axy51Doo39VywvpPInRjhhAacGyZHhZROQscIjdC13dBBOqnY5J5XHZQ98QLcxkhM-znZz_IsfkE0w3ECA2-MKEgjMULuxglSISJ5ZGIabWKpL8oiyXyPB7DMmApxvGaVGBiKgQkxtMmHutFcEL_cfrujRMVUTjOswgwweHsz-rtmcSEnlIKZrLCYwS4QPYh3C1Zl26J-m3h1S6ksCyX4712-AyTV74T08gBohnUbOLfJWwU0BusNbiLyLM6XBcMQEhyJR9vkUACvfhaYgmA9eDa81RYktzrbvpKl04rTnvqBaxvey7sM7hV5sJk3XpP9crGM35B70apMi8UR2aNj_0j-DX8CEhUQtg |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+MOG-IgG-associated+disorder+with+rituximab%3A+an+international+study+of+121+patients&rft.jtitle=Multiple+sclerosis+and+related+disorders&rft.au=Whittam%2C+Daniel&rft.au=Cobo-Calvo%2C+Alvaro&rft.au=Lopez-Chiriboga%2C+a+Sebastian&rft.au=Pardo%2C+Santiago&rft.date=2020-09-01&rft.pub=Elsevier&rft.issn=2211-0356&rft.eissn=2211-0348&rft.volume=44&rft_id=info:doi/10.1016%2Fj.msard.2020.102251&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=oai%3AHAL%3Ahal-03344233v1 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F22110348%2FS2211034820X0006X%2Fcov150h.gif |